Market Cap 121.27M
Revenue (ttm) 0.00
Net Income (ttm) -61.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 271,500
Avg Vol 1,491,648
Day's Range N/A - N/A
Shares Out 35.99M
Stochastic %K 6%
Beta 0.37
Analysts Strong Sell
Price Target $11.42

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8080
Address:
245 Main Street, Second Floor, Cambridge, United States
OptimistJP
OptimistJP Aug. 4 at 12:43 PM
$IMRX earnings report date: Earnings Whispers says August 12th ETrade web site says August 5th Seeking Alpha says August 8th
0 · Reply
OptimistJP
OptimistJP Aug. 1 at 4:13 PM
$IMRX back above $4 before earnings? Hoping so. Opti
1 · Reply
CAN_2409
CAN_2409 Aug. 1 at 10:03 AM
$IMRX >>> CADL
0 · Reply
justme_DC
justme_DC Jul. 31 at 9:03 PM
$IMRX While I am typically very critical of blaming shorts or hoping for some lottery ticket short squeeze. I do notice over the last several days the start of a pattern. Shortly before noon, a few hundred thousand shorts are taken out and then returned ~hour and a half later. I doubt anyone from the company reads these silly posts on stocktwits.....but as far as perfect timing, seems that it would be awesome to post some (material and real) news right about 12:15 and get a nice little burn from whoever is doing that. Oh well....grrrrr.....it is a long ways until P3. It needs something to give it some action or drum up buyer interest.
1 · Reply
OptimistJP
OptimistJP Jul. 31 at 2:08 PM
$IMRX watch the August 5, 2025, earnings report for updates on IMM-1-104’s Phase 2a trial. Positive data could reverse the decline.
0 · Reply
OptimistJP
OptimistJP Jul. 31 at 2:05 PM
$IMRX Strange happenings. All the stocks I follow (the list is a mix of drone, AI, and IMRX specifically) have been falling slowly but steadily over the past week. Now they all suddenly have fairly large spreads between the bid and ask, in the range of 5 cents or more. Just strange that they all are acting so similarly.
0 · Reply
justme_DC
justme_DC Jul. 30 at 9:07 PM
$IMRX Bless their hearts LOL. The guys in their underwear in their momma's basement saying "look momma, I just swung a publically traded company 15% with a fee hundred dollars!!!" Grrrr....does show that IMRX has to post some material / significant PR's to get some interest and liquidity....
0 · Reply
Eruption
Eruption Jul. 30 at 7:21 PM
$IMRX Unf**ing real. Shorters are such a-holes. F***!
1 · Reply
SpittingImage
SpittingImage Jul. 29 at 10:38 PM
$IMRX sittin. Waitin. Wishin. Cryin.
1 · Reply
Eruption
Eruption Jul. 29 at 7:21 PM
$IMRX Geezus.....ugh!!!!
0 · Reply
Latest News on IMRX
Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 4 months ago

Immuneering Corporation Announces Grant of Inducement Award


Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 4 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer


Why Is Immuneering Stock Trading Higher On Tuesday?

Jan 7, 2025, 9:28 AM EST - 7 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?


Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 8 months ago

Immuneering Launches Pancreatic Cancer Advisory Board


Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month


Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.


Immuneering to Present at the Jefferies Healthcare Conference

May 30, 2023, 8:00 AM EDT - 2 years ago

Immuneering to Present at the Jefferies Healthcare Conference


Immuneering Announces $30 Million Underwritten Offering

Apr 18, 2023, 9:24 AM EDT - 2 years ago

Immuneering Announces $30 Million Underwritten Offering


OptimistJP
OptimistJP Aug. 4 at 12:43 PM
$IMRX earnings report date: Earnings Whispers says August 12th ETrade web site says August 5th Seeking Alpha says August 8th
0 · Reply
OptimistJP
OptimistJP Aug. 1 at 4:13 PM
$IMRX back above $4 before earnings? Hoping so. Opti
1 · Reply
CAN_2409
CAN_2409 Aug. 1 at 10:03 AM
$IMRX >>> CADL
0 · Reply
justme_DC
justme_DC Jul. 31 at 9:03 PM
$IMRX While I am typically very critical of blaming shorts or hoping for some lottery ticket short squeeze. I do notice over the last several days the start of a pattern. Shortly before noon, a few hundred thousand shorts are taken out and then returned ~hour and a half later. I doubt anyone from the company reads these silly posts on stocktwits.....but as far as perfect timing, seems that it would be awesome to post some (material and real) news right about 12:15 and get a nice little burn from whoever is doing that. Oh well....grrrrr.....it is a long ways until P3. It needs something to give it some action or drum up buyer interest.
1 · Reply
OptimistJP
OptimistJP Jul. 31 at 2:08 PM
$IMRX watch the August 5, 2025, earnings report for updates on IMM-1-104’s Phase 2a trial. Positive data could reverse the decline.
0 · Reply
OptimistJP
OptimistJP Jul. 31 at 2:05 PM
$IMRX Strange happenings. All the stocks I follow (the list is a mix of drone, AI, and IMRX specifically) have been falling slowly but steadily over the past week. Now they all suddenly have fairly large spreads between the bid and ask, in the range of 5 cents or more. Just strange that they all are acting so similarly.
0 · Reply
justme_DC
justme_DC Jul. 30 at 9:07 PM
$IMRX Bless their hearts LOL. The guys in their underwear in their momma's basement saying "look momma, I just swung a publically traded company 15% with a fee hundred dollars!!!" Grrrr....does show that IMRX has to post some material / significant PR's to get some interest and liquidity....
0 · Reply
Eruption
Eruption Jul. 30 at 7:21 PM
$IMRX Unf**ing real. Shorters are such a-holes. F***!
1 · Reply
SpittingImage
SpittingImage Jul. 29 at 10:38 PM
$IMRX sittin. Waitin. Wishin. Cryin.
1 · Reply
Eruption
Eruption Jul. 29 at 7:21 PM
$IMRX Geezus.....ugh!!!!
0 · Reply
justme_DC
justme_DC Jul. 29 at 6:50 PM
$IMRX Low volume since the middle of June. Great P2 results and great potential. Big key will be how much they have raised since then to improve their cash runway and if any partnerships come about between now and P3 (2026). They are in a favorable position for interest with those P2 results....but thinking that SP will gradually decline over the next year unless they can provide some other significant catalyst (occassional short term spikes excluded). Time will tell. Let's hope for some material news sooner rather than later.
0 · Reply
tgewaz1
tgewaz1 Jul. 29 at 2:31 PM
$IMRX https://www.investing.com/news/analyst-ratings/celcuity-stock-price-target-raised-to-50-from-27-at-hc-wainwright-93CH-4157138 Join the road to 60.00
0 · Reply
Eruption
Eruption Jul. 29 at 2:15 PM
$IMRX Tjis is being tanked on purpose. I assume until the earnings release next week. So frustrating.
0 · Reply
JerryDalio
JerryDalio Jul. 29 at 1:07 PM
$IMRX you need to buy the crap out of this because I’m gonna short it now
0 · Reply
TheStoicOne
TheStoicOne Jul. 28 at 2:39 PM
$IMRX I'll get some more today why not
1 · Reply
justme_DC
justme_DC Jul. 24 at 8:07 PM
$IMRX Maybe just me. But anyone else noticed (past 2 weeks) bounce between ~$4 and ~4.30. IMO ONLY.....(this is will be the 4th time I have scalped) that it seems that they may be selling their ATM but intentionally keeping it in the ~$4 range?? This is not bashing. I honestly view this as very bullish in potential. Now if they break and stay below the $3.95 range....will not be so bullish
2 · Reply
Smittysixty
Smittysixty Jul. 21 at 4:16 PM
$PPBT — They group it to justify the move. Don’t fall for the tactic. You’re seeing $PPBT tossed into biotech blends with $PMN $SLS $IMRX — but that’s not validation, it’s narrative engineering. The tactic is simple: camouflage real strength with early-stage fluff. 💡 Purple Biotech isn’t chasing hope—it’s delivering: • Phase 2 survival data in pancreatic cancer? ✅ • CAPTN-3 tri-specific antibody targeting solid tumors via T & NK cell activation? ✅ • IP expansion, multiple shots on goal, cash runway to 2026? ✅ The rest? • $PMN is preclinical in Alzheimer’s. • $SLS has peptide vaccines still grinding through trials. • $IMRX is modeling transcriptomes in Phase 1. This isn’t just “one of the group.” $PPBT is the outlier in clinical maturity, strategic targeting, and undervaluation. Posts that bundle $PPBT with low-traction biotech names are masking how far ahead it really is. Watch the signal—not the smokescreen. 👊🧬
3 · Reply
BinaryLogic
BinaryLogic Jul. 20 at 6:17 PM
$SCNX [5-10X Valuation] Go onto GoodRx (below), and search for Arbli - you will see it priced in every domestic (US) market across every major pharmacy chain, which means that it is commercially available. A quick DCF (2025-2041) of SCNX assuming a $350-500Mils Losartan Market today (2025), 2.5% CAGR, 16% Penetration of Liquid formulation (Arbli, exclusivity to 2041), 10-15% Net Margin, 10% WACC and 1:1 NM to Unlevered FCF (all reasonable if not conservative assumptions), you will see a valuation here of $240-300Mils. This is just for Arbli - it assumes absolutely nothing for Rezenopy (also shown on GoodRx, but not yet with pricing/availability), or any other drugs currently in the Corporate pipeline. The Company is presently valued at $27MILS. 5-10X (IMO) from this level - and this is the math to prove it. Compare the valuations: $VTYX: $225MILS $IMRX: $149MILS $DRUG: $189MILS $RGC: $7.2Bils https://www.goodrx.com/arbli?srsltid=AfmBOoqklh6SZAag6dP2XoL_iyutunHKw5yA7S-un_BopP1bV9Tp3Xdc
3 · Reply
JerryDalio
JerryDalio Jul. 20 at 7:00 AM
$IMRX Potential Scenarios • Breakout: A sustained move above $4.60 with increased volume could signal a breakout, potentially targeting analyst price targets around $10.88–$13.25 (based on analyst consensus). • Pullback: A drop below $4.00 with higher volume might indicate a deeper pullback toward $3.78 or lower support levels, especially if negative news emerges or market sentiment shifts. • Consolidation: The current indecision could persist, with the stock trading sideways until a catalyst (e.g., earnings on August 6, 2025, or trial updates) provides direction. 🌟 The long-term trend for IMRX remains bullish, supported by clinical progress and analyst optimism. However, the short-term trend is in a consolidation phase, with a risk of a low-volume pullback or a potential breakout depending on volume and news flow. Monitoring volume, support at $4.00, and resistance at $4.60 will be critical. Would you like me to focus on a specific aspect, such as volume trends or upcoming events?
1 · Reply
LolloTek
LolloTek Jul. 17 at 7:53 PM
$IMRX nice candle before market close 📈
0 · Reply
SpittingImage
SpittingImage Jul. 17 at 1:47 PM
$IMRX let it EAT!
0 · Reply
OptimistJP
OptimistJP Jul. 17 at 12:46 AM
$IMRX On August 10, 2022, the Company entered into an Equity Distribution Agreement (the "Sales Agreement") with Piper Sandler & Co (the "Sales Agent"), to sell shares of its common stock with aggregate gross proceeds of up to $50 million, from time to time, through an “at the market” equity offering program ("ATM Program"). The Company sold 4,836,804 shares of common stock under the ATM Program, at an average price per share of $2.95, for aggregate gross proceeds of $14,248,741 ($13,676,667 net of offering expenses) during the three months ended March 31, 2025. I cannot find information on how much of the ATM is still available. I guess we will find out more in August.
1 · Reply